Table 4:
Dosing and Reasons for Treatment Discontinuation
Number of Patients (%) | |
---|---|
Total Evaluable | 31 (100) |
800mg | 13 (42) |
600mg | 12 (39) |
400mg | 6 (19) |
Reason off therapy | 32 (100) |
Transaminitis | 4 (13) |
Other toxicities | 3 (10) |
Progression | 6 (20) |
Patient choice | 11 (35) |
Ongoing treatment | 7 (32) |
Death | 1 (3) |